REFERENCES

Human strain on deposit at the American Type Culture Collection as SD5219.

1) BL-34 has been genetically characterized as B. lactis using

    PCR: Appl. Environ. Microbiol., 2002, Vol. 68 (12), pp 6429-6434.

2) B. lactis is on the EU Safety List for human consumption:

    www.efsa.europa.eu/EFSA/Scientific_Opinion/sc_op_ej587_qps_en.pdf

3) Safety of Probiotics that contain Lactobacilli and Bifidobacteria (THERALAC):

    Clinical Infective Disease, 2003, Vol. 36, pp 775-780.

4) BL-34, plus 3 other Theralac® strains, stabilizes intestinal microflora during

    and after Augmentin treatment: J. Med. Microbiol., 2009, 58, 663-670.

5) BL-34 is stimulated in vivo in elderly patients by the prebiotic inulin:

    Clinical Infectious Diseases, 2005, Vol. 40, pp 28-37.

6) BL-34 enhances the production of the anti-inflammatory cytokine IL-10:

    World J. Gastroenterology, 2007, Vol. 13 (2), pp 326-243.

7) BL-34 up-regulates Th2 or humoral immunity: FEMS Immunol.

    and Medical Microbiol., 2003, Vol. 38, pp 165-172.